Peripheral neuropathy: Zalcitabine reassessed

International Journal of STD and AIDS

Volumn 11, Issue 7, 2000, Pages 417-423

  Carey, Peter ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; HAART; HIV; Peripheral neuropathy; Zalcitabine

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; EPVIR; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; TABLET;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; ZALCITABINE;

EID: 0034084875     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462001916128     Document Type: Review

References (49)

1. 1 French Department of Health. Prise en charge thérapeutique des personnes infectées par le VIH. Rapport 1999. Recommandations du groupe d'experts. http://www.sante.gouv.fr/htm/dossiers/sidahop/index_delfra.htm
2. 2 Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society. JAMA 2000;283:381-90
3. 3 Doctor Fax. New French guidelines for antiretroviral treatment. Issue 75, 17 September 1999. http://www.atp.org.uk/df75.html
4. 4 PRN Notebook. New French guidelines for antiretroviral treatment. Vol IV, No. 4, December 1999. http://www.prn.org/ prn_nb_cntnt/vol4/num4/article4_frm_set.htm
5. 5 Adkins JC, Peters DH, Faulds D. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 1997;53:1054-80
6. 6 Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998;19:481-94
7. 7 Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994;44:1892-900
8. 8 Schültz M, Wendrow A. Quick reference guide to antiretrovirals. January 2000. http://hiv.medscape.com/updates/quickguide
9. 9 Nauss-Karol C, Salgo M, Liederman J, et al. Expanded access experience with dideoxycytidine (ddC). AIDS 1992;6(suppl 1):S29
10. 10 Follansbee S, Drew L, Olsen R, et al. The efficacy of zalcitabine (ddC, HIVID) versus zidovudine (ZDV) as monotherapy in ZDV naïve patients with advanced HIV disease: a randomized, double-blind, comparative trial (ACTG 114: N3300). 9th International Conference on AIDS, Berlin 1993
11. 11 Fischl MA, Olsen RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993;118:762-9
12. 12 Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994;330:657-62
13. 13 Torres RA, Barr MR, McIntyre KI, et al. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease. Int J STD AIDS 1995;6:19-26
14. 14 Moyle G, Goll A, Snape S, et al. Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European Expanded Access Programme. Int J Antimicrob Ag 1996;7:41-8
15. 15 Pike IM, Nicaise C. The didanosine expanded access program: safety analysis. Clin Infect Dis 1993;16(suppl 1): S63-8
16. 16 Perry CM, Balfour JA. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs 1996;52:928-62
17. 17 Hurst M, Noble S. Stavudine. An update of its use in the treatment of HIV infection. Drugs 1999;58:919-49
18. 18 Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995;122:24-32
19. 19 Gottlieb M, Peterson D, Adler M. Comparison of safety and efficacy of 2 doses of stavudine (Zerit, stavudine) in a large simple trial in the US parallel track programme. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 1995
20. 20 Peterson EA, Ramirez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with the human immunodeficiency virus. J Infect Dis 1995;171(suppl 2):S131-9
21. 21 Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:153-61
22. 22 Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995; 171(suppl 2):S113-17
23. 3. Antiviral Ther 1996;1:180-8
24. 24 Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine experienced patients: a randomized, double-blind, controlled trial. Ann Intern Med 1997; 126:355-63
25. 25 Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335: 1081-90
26. 26 Kroon E, Chuenyam M, Van Leeuwen R. Study HIV-NAT 001: A randomized double-blind, comparative trial to evaluate the efficacy of combination antiviral therapy with ZDV 200 mg TID plus ddC 0.75 mg TID versus ZDV 100 mg TID plus ddC 0.375 mg TID for the treatment of HIV-1 infection in a Thai population. 12th World AIDS Conference, Geneva 1998
27. 27 Katlama C, Pellegrin J-L, Lacoste D, et al. MIKADO: A multicentre, open-label, pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine. HIV Med 2000 (in press)
28. 28 Stellbrink H-J on behalf of the Invirase International Phase III Trial (SV-14604) Group. Clinical and survival benefit of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg 1997
29. 29 Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91
30. 30 Simpson DM, Katzenstein DA, Hughes MD, et al. Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS 1998;12:2425-32
31. 31 Raffi F, Reliquet V, Auger S, et al. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients. AIDS 1998;12:1999-2005
32. 32 Moore R, Keruly J, McArthur J, Chaison R. Incidence of neuropathy in HIV-infected patients taking monotherapy vs combination therapy with didanosine, stavudine, and hydroxyurea. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco 2000
33. 33 Berger AR, Arezzo JC, Schaumburg HH, et al. 2′,3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993;43:358-62
34. 34 Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and polyneuropathy. Neurology 1999;52:607-13
35. 35 Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:169-74
36. 36 Blum AS, Dal PGJ, Feinberg J, et al. Low-dose zalcitabine related toxic neuropathy: frequency, natural history and risk factors. Neurology 1996;46:999-1003
37. 37 Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cell counts per cubic millimeter. N Engl J Med 1996;335:1099-106
38. 38 Haubrich R, Lalezari J, Follansbee SE, et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998;3:33-42
39. 39 Mathez D, Bagnarelli P, Gorin I, et al. Reductions in viral load and increases in T lymphocyte numbers in treatment-naïve patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Antiviral Ther 1997;2:175-83
40. 40 Lantz O, Martinon F, Peguillet I, et al. Longitudinal analysis of the immune reconstitution after HAART (saquinavir-SGC, d4T and ddC) initiation in previously untreated patients (MIKADO). 12th World AIDS Conference, Geneva 1998
41. 41 Masuhr A, Arasteh K, Simon V, et al. Detection of genotypic drug resistance to antiviral nucleoside inhibitors in short-time pretreated and drug-naïve HIV-1 infected patients as predictor of treatment failure in high acting antiretroviral therapy (HAART). 12th World AIDS Conference, Geneva 1998
42. 42 Craig C, Moyle G. The development of resistance of HIV-1 to zalcitabine. AIDS 1997;11:271-9
43. 43 Brun-Vézinet F, Boucher C, Loveday C, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naïve participants from the Delta trial. Lancet 1997;350:983-90
44. 44 García F, Romeu J, Grau I, et al. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1 infected patients in very early stage disease: the Spanish Earth-1 study. AIDS 1999;13:2377-88
45. 45 Katzenstein D, Bosch R, Shafer R, et al. Virological response to nelfinavir, efavirenz, or both in patients with >4 years of previous nucleoside RT inhibitors in ACTG 364. Antiviral Ther 1999;4(suppl 1):47
46. 46 Quattro Steering Committee. A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection - The Quattro Trial. AIDS 1999;13:2209-17
47. 47 Kroon EDMB, Ungsedhapand C, Worarien W, et al. A randomized, open label, follow-up study to explore the antiretroviral efficacy and tolerability of switching to therapy with d4T/ddI/saquinavir-SG soft gel versus combivir/saquinavir-SG soft gel in an HIV infected Thai population pretreated with AZT/ddC. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco 2000
48. 48 Moyle G, Gill J, Nelson M. Use of zalcitabine in twice daily dosing regimens. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 1998
49. 49 Mobley JE, Pollard RB, Schrader S, et al. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AIDS 1999;13: F87-93